NeoGenomics Completes Acquisition of Genoptix, Inc.

NeoGenomics Announces Participation in NCI-MATCH Clinical Trial

NeoGenomics Awarded Clinical Reference Laboratory Testing Services Agreement with Premier

Oct 30, 2018 • 7:00 AM EDT

Q3 2018 Quarterly Results

Quarter Ended Sep 30, 2018

17% increase in consolidated revenue

14% increase in clinical genetic testing volume

21% increase in Pharma Services revenue

Announced acquisition of Genoptix

PPD and NeoGenomics Forming Global Strategic Alliance for Pathology and Molecular Testing Solutions

Company Profile

NeoGenomics, Inc. is a high-complexity CLIA-certified clinical laboratory and pharma services company that specializes in cancer genetics diagnostic testing, the fastest growing segment of the laboratory industry. The company's testing services include cytogenetics, fluorescence in-situ hybridization (FISH), flow cytometry, immunohistochemistry, anatomic pathology, and molecular genetics. Headquartered in Fort Myers, FL, NeoGenomics maintains a network of testing facilities across the US. NeoGenomics services the needs of pathologists, oncologists, urologists and other physician specialists, academic institutions, and the pharmaceutical industry.

Latest 10-K

View Latest 10-K

NeoGenomics, Inc.

Nasdaq: NEO

Market/Symbol

Price

Change

Volume

Day Range

52 week Range

IR Contact Information

Investor Relations William Bonello
Chief Strategy and Corporate Development Officer
Director, Investor Relations
T: (239) 690-4238
M: (239) 284-4314
bill.bonello@neogenomics.com

Transfer Agent Standard Registrar & Transfer Company
12528 South 1840 East
Draper, UT 84020
T: (801) 571-8844